Identification of Two M6A Readers and As Immune Biomarkers in Head and Neck Squamous Cell Carcinoma

Overview

Journal Front Genet

Date 2022 Jun 1

PMID 35646049

Authors

Shaojie Li

Qiuji Wu

Jia Liu

Yahua Zhong

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (m6A) is the most abundant internal modification pattern in mammals that a plays critical role in tumorigenesis and immune regulations. However, the effect of m6A modification on head and neck squamous cell carcinoma (HNSCC) has not been clearly studied. We screened m6A regulators that were significantly correlated with tumor immune status indicated by ImmuneScore using The Cancer Genome Atlas (TCGA) dataset and obtained distinct patient clusters based on the expression of these m6A regulators with the R package "CensusClusterPlus." We then performed gene set enrichment analysis (GSEA), CIBERSORT, and single-sample gene set enrichment analysis (ssGSEA) to assess the differences in gene function enrichment and tumor immune microenvironment (TIME) among these clusters. We further conducted differently expressed gene (DEG) analysis and weighted gene co-expression network analysis (WGCNA) and constructed a protein-protein interaction (PPI) network to determine hub genes among these clusters. Finally, we used the GSE65858 dataset as an external validation cohort to confirm the immune profiles related to the expression of m6A regulators. Two m6A readers, and , were found to be significantly associated with distinct immune status in HNSCC. Accordingly, patients were divided into two clusters with Cluster 1 showing high expression of and and Cluster 2 showing low expression levels of both genes. Clinicopathologically, patients from Cluster 1 had more advanced T stage and pathological grades than those from Cluster 2. GSEA showed that Cluster 1 was closely related to the RNA modification process and Cluster 2 was significantly correlated with immune regulations. Cluster 2 had a more active TIME characterized by a more relative abundance of CD8 T cells and CD4 T cells and higher levels of MHC I and MHC II molecules. We constructed a PPI network composed of 16 hub genes between the two clusters, which participated in the T-cell receptor signaling pathway. These results were externally validated in the GSE65858 dataset. The m6A readers, and were potential immune biomarkers in HNSCC and could be potential treatment targets for cancer immunotherapy.

Citing Articles

Multifaceted roles of insulin‑like growth factor 2 mRNA binding protein 2 in human cancer (Review).

Shen J, Ding Y Mol Med Rep. 2025; 31(3).

PMID: 39886962 PMC: 11795254. DOI: 10.3892/mmr.2025.13441.

Construction and clinical application of a risk model based on N6-methyladenosine regulators for colorectal cancer.

Zhu H, Yang Y, Zhou Z PeerJ. 2024; 12:e18719.

PMID: 39717046 PMC: 11665428. DOI: 10.7717/peerj.18719.

SLC50A1 inhibits the doxorubicin sensitivity in hepatocellular carcinoma cells through regulating the tumor glycolysis.

Wang G, Jin W, Zhang L, Dong M, Zhang X, Zhou Z Cell Death Discov. 2024; 10(1):495.

PMID: 39695152 PMC: 11655560. DOI: 10.1038/s41420-024-02261-3.

N6-methyladenosine RNA modification in head and neck squamous cell carcinoma (HNSCC): current status and future insights.

Janakiraman P, Jayaprakash J, Muralidharan S, Narayan K, Khandelia P Med Oncol. 2024; 42(1):12.

PMID: 39580759 DOI: 10.1007/s12032-024-02566-4.

A comprehensive prognostic score for head and neck squamous cancer driver genes and phenotype traits.

Zeng W, Xie F, Pan Y, Chen Z, Chen H, Liu X Discov Oncol. 2023; 14(1):193.

PMID: 37897503 PMC: 10613197. DOI: 10.1007/s12672-023-00796-y.

References

Dixit D, Prager B, Gimple R, Poh H, Wang Y, Wu Q . The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2020; 11(2):480-499. PMC: 8110214. DOI: 10.1158/2159-8290.CD-20-0331. View

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

Visvanathan A, Patil V, Arora A, Hegde A, Arivazhagan A, Santosh V . Essential role of METTL3-mediated mA modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2017; 37(4):522-533. DOI: 10.1038/onc.2017.351. View

Chow L . Head and Neck Cancer. N Engl J Med. 2020; 382(1):60-72. DOI: 10.1056/NEJMra1715715. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Citri A, Yarden Y . EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-16. DOI: 10.1038/nrm1962. View

Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R . YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2018; 442:252-261. DOI: 10.1016/j.canlet.2018.11.006. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

10.

Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y . The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020; 48(7):3816-3831. PMC: 7144925. DOI: 10.1093/nar/gkaa048. View

11.

Esensten J, Helou Y, Chopra G, Weiss A, Bluestone J . CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016; 44(5):973-88. PMC: 4932896. DOI: 10.1016/j.immuni.2016.04.020. View

12.

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

13.

Li B, Zhu L, Lu C, Wang C, Wang H, Jin H . circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021; 12(1):295. PMC: 7804955. DOI: 10.1038/s41467-020-20527-z. View

14.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

15.

Zaccara S, Ries R, Jaffrey S . Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019; 20(10):608-624. DOI: 10.1038/s41580-019-0168-5. View

16.

Hegde P, Chen D . Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020; 52(1):17-35. DOI: 10.1016/j.immuni.2019.12.011. View

17.

Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R . m A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020; 39(20):e104514. PMC: 7560214. DOI: 10.15252/embj.2020104514. View

18.

Vu L, Pickering B, Cheng Y, Zaccara S, Nguyen D, Minuesa G . The N-methyladenosine (mA)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017; 23(11):1369-1376. PMC: 5677536. DOI: 10.1038/nm.4416. View

19.

Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H . Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2014; 43(1):373-84. PMC: 4288171. DOI: 10.1093/nar/gku1276. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View